Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VIP-943 by Vincerx Pharma for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
VIP-943 by Vincerx Pharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
VIP-943 by Vincerx Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
VIP-943 by Vincerx Pharma for Myelodysplastic Syndrome: Likelihood of Approval
VIP-943 is under clinical development by Vincerx Pharma and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...